Appetite stimulants for people with cystic fibrosis

Chinuck, R.S.; Dewar, J.; Fortnum, Heather; Baldwin, David R; McKeever, Tricia M.

doi:10.1002/14651858.cd008190

Cited by 3 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature on choice, style of prescribing, and duration of appetite‐stimulating medications is limited 11,12 . Our survey showed that cyproheptadine was the preferred initial choice of appetite stimulant but revealed a lack of consistent length of use or end points to determine success and/or when to wean off these medications.…”

Section: Discussionmentioning

confidence: 92%

Variations in Nutrition Practices in Cystic Fibrosis: A Survey of the DIGEST Program

2020

View full text Add to dashboard Cite

Background Evidence‐based management of gastrointestinal (GI) and nutrition manifestations of cystic fibrosis (CF) is limited, and practice variations have not been studied. Methods Thus, a survey was developed with the purpose of evaluating current nutrition practices of CF‐focused gastroenterologists, specifically utilizing awardees and mentors of the Cystic Fibrosis Foundation (CFF) Developing Innovative GastroEnterology Specialty Training (DIGEST) Program. Topics included appetite stimulation, tube feeding (TF), and aspects of nutrition assessment, specifically urine sodium and essential fatty acid (EFA) status. Results The response rate was 61% (22/36). About half (55%; 12/22) of respondents had 5–10 years of experience in GI, and 23% (5/22) had >10 years. In regard to appetite stimulation, the majority used cyproheptadine; however, duration and pattern of prescribing varied. Variation was noted in TF management pertaining to tube placement, formula choice, and prescribing pancreatic enzyme replacement therapy with overnight TF. The majority did not check EFAs or urine sodium. Treatment for deficiencies in EFA or abnormal urine sodium was inconsistent. Conclusion The survey reveals wide variation in management of some aspects of nutrition‐related manifestations of CF among experienced providers. This reflects the need for research to provide evidence‐based guidelines.

show abstract

Section: Discussionmentioning

confidence: 92%

Variations in Nutrition Practices in Cystic Fibrosis: A Survey of the DIGEST Program

2020

View full text Add to dashboard Cite

show abstract

“…; Chinuck et al . ). Progesterone‐containing treatments stimulate the activity of lipoprotein lipase that may enhance fat deposition and alter plasma lipids, producing weight gain.…”

Section: Amelioration Of Pew In Patients With Ckdmentioning

confidence: 97%

Using megestrol acetate to ameliorate protein‐energy wasting in chronic kidney disease

Smith

Logomarsino

2015

Journal of Renal Care

View full text Add to dashboard Cite

show abstract

“…Appetite stimulants such as cyproheptadine may improve appetite and result in weight gain in people with CF . For children who have a chronic loss of appetite, appetite stimulants may be considered for a short duration of 4–6 months once other strategies to improve nutritional status, such as PERT optimisation and nutrition education, have been explored.…”

Section: Nutritionmentioning

confidence: 99%

Practical approach to the gastrointestinal manifestations of cystic fibrosis

Bolia

Ooi

Lewindon

et al. 2018

J Paediatrics Child Health

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common, life-shortening, genetic illness affecting children in Australia and New Zealand. The genetic abnormality results in abnormal anion transport across the apical membrane of epithelial cells in a number of organs, including the lungs, gastrointestinal tract, liver and genito-urinary tract. Thus, CF is a multi-system disorder that requires a multi-disciplinary approach. Respiratory disease is the predominant cause of both morbidity and mortality in patients with CF. However, there are significant and clinically relevant gastrointestinal, liver, pancreatic and nutritional manifestations that must be detected and managed in a timely and structured manner. The aim of this review is to provide evidence-based information and clinical algorithms to guide the nutritional and gastrointestinal management of patients with CF.

show abstract

Appetite stimulants for people with cystic fibrosis

Cited by 3 publications

References 30 publications

Variations in Nutrition Practices in Cystic Fibrosis: A Survey of the DIGEST Program

Variations in Nutrition Practices in Cystic Fibrosis: A Survey of the DIGEST Program

Using megestrol acetate to ameliorate protein‐energy wasting in chronic kidney disease

Practical approach to the gastrointestinal manifestations of cystic fibrosis

Contact Info

Product

Resources

About